The Wall Street Transcript
The Wall Street Transcript - In-Depth Interviews for Investors
Healthcare >> CEO Interviews >> April 22, 2016

Interview with the CEO: Tobira Therapeutics Inc. (NASDAQ:TBRA)

Fischer, Laurent
Laurent Fischer joined the board of directors of Tobira Therapeutics Inc. in April 2009 and became the company’s Chief Executive Officer in 2014. Dr. Fischer brings 20 years of drug development and commercialization experience in the biopharmaceutical industry. Prior to joining Tobira full time as CEO, he was Chairman and Chief Executive Officer of Jennerex, Inc., a private, clinical-stage biotherapeutics company focused on the development of targeted oncolytic immunotherapy products for liver cancer that was sold for up to $150 million. Prior to Jennerex, he was Co-Founder, President and CEO of Ocera Therapeutics (NASDAQ:OCRX), where he licensed and developed OCR-002, the first ammonia scavenger for the treatment of complications of liver disease. Dr. Fischer has co-founded and managed four health care companies and held senior management positions at DuPont-Merck, DuPont Pharmaceuticals and Hoffmann-La Roche in liver disease, virology and oncology. Dr. Fischer led the team responsible for the global launch of Sustiva, the first once-daily anti-HIV therapy, now part of the fixed-dose combination therapy Atripla, and was involved in the launch of Invirase, the first protease inhibitor in the United States. Dr. Fischer received his undergraduate degree from the University of Geneva and his medical degree from the Geneva Medical School, Switzerland. Profile
TWST: Please start by giving our readers a snapshot of Tobira Therapeutics’ history and its current focus.

Dr. Fischer: Tobira Therapeutics is a biotech company located in South San

Top Company Interviews

Microsoft Corporation
Intel Corporation
Pfizer, Inc.
General Electric Company
Walmart Inc.
International Business Machines Corporation
Citigroup Inc.
Exxon Mobil Corporation
Bank of America Corporation
Dell Inc.
Verizon Communications Inc.
Alphabet Inc

Register for a Free Account to gain greater access to The Wall Street Transcript right now

CEO INTERVIEWS
Interview with the CEO: Pasithea Therapeutics Corp. (NASDAQ:KTTA)
Interview with the CEO: BetterLife Pharma Inc. (OTCMKTS:BETRF)
Interview with the CEO: Cansortium Inc. (OTCMKTS:CNTMF)
SECTOR ROUNDTABLES
Natural Gas Weighs Heavy On E&P Near-Term Prospects
Roundtable Forum:optimism Despite Uncertainty In For-profit Education
Roundtable Forum:a Shift In Focus To Natural Gas From Oil
MONEY MANAGER INTERVIEWS
Profitability Strategy Pays Off for Bank IT Company Q2 Holdings
Three Mid-Cap Names Using Their Balance Sheets to Create Value
Look Beyond Traditional Emerging Markets for More Diversification, Less Risk
ANALYST INTERVIEWS
Five Companies Dominate in Psychedelics-Based Drug Development
Cidara’s Long-Acting Antiviral Drug Could Be a Game Changer
Spotting Potential in the High-Risk, High Reward Neuroscience Space
Since 1963
© The Wall Street Transcript 2016, 2024
Terms and Conditions
Privacy Policy